# Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination

Researcher: Ge Zhang
Chinese name: 张格
ORCID identity anchor: https://orcid.org/0000-0002-3116-3246
Canonical researcher: https://drgezhang.com/#person

Journal: Cancer Letters
Year: 2024
Type: Article
DOI: 10.1016/j.canlet.2024.217079
Canonical page: https://drgezhang.com/papers/icd-cart.html
Markdown record: https://drgezhang.com/papers/icd-cart.md

## Full Authors

1. Zhaokai Zhou
2. Yumiao Mai
3. Ge Zhang
4. Yingjie Wang
5. Pan Sun
6. Zhaohe Jing
7. Zhengrui Li
8. Yudi Xu
9. Bo Han
10. Jian Liu

## About this record

This is an author-controlled publication record in the Ge Zhang Academic Hub. It identifies this work as part of Ge Zhang’s publication record via ORCID; the publisher version remains the version of record.

<a id="limited-evidence"></a>
## Research context and source limits

Limited evidence note. Only the source material identified below has been reviewed; this is not a complete Paper GEO V2 assessment.

Abstract-supported review context; the complete review and its cited experimental evidence have not been audited.

### Review question

This review considers immunogenic cell death as a possible partner for CAR-T strategies in solid tumors. Its abstract connects stress-induced release of damage-associated molecular patterns with the immune environment and describes antigen heterogeneity and physical or immune barriers as challenges for CAR-T cells.

Source: [PubMed PMID 38936505, Abstract: opening rationale and solid-tumor barriers.](https://pubmed.ncbi.nlm.nih.gov/38936505/)

### Evidence level

The article is a review of mechanisms and proposed combination approaches, not a new clinical trial. Its discussion of potential synergy should be distinguished from demonstrated patient benefit for a specific regimen.

Source: [PubMed PMID 38936505, Abstract: final sentence identifying the review scope; publication type Review.](https://pubmed.ncbi.nlm.nih.gov/38936505/)

### Evidence limits

- Specific combinations, experimental models and effect sizes require the complete review and the relevant primary studies. The available abstract cannot establish prospective clinical efficacy or safety.

### Provenance

- [Indexed article abstract](https://pubmed.ncbi.nlm.nih.gov/38936505/) — PubMed abstract, refreshed through the official Europe PMC API. PubMed PMID 38936505, Abstract: opening rationale and solid-tumor barriers.

Source review: 2026-10-27.

## Cite this paper

Zhaokai Zhou, Yumiao Mai, Ge Zhang, Yingjie Wang, Pan Sun, Zhaohe Jing, Zhengrui Li, Yudi Xu, Bo Han, Jian Liu. Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination. Cancer Letters. 2024. https://doi.org/10.1016/j.canlet.2024.217079

- [BibTeX](https://drgezhang.com/citations/icd-cart.bib)
- [RIS / EndNote](https://drgezhang.com/citations/icd-cart.ris)
- [CSL JSON](https://drgezhang.com/citations/icd-cart.csl.json)

## Links

- DOI: https://doi.org/10.1016/j.canlet.2024.217079
- HTML page: https://drgezhang.com/papers/icd-cart.html
- Google Scholar query: https://scholar.google.com/scholar?q=%22Emerging%20role%20of%20immunogenic%20cell%20death%20in%20cancer%20immunotherapy%3A%20Advancing%20next-generation%20CAR-T%20cell%20immunotherapy%20by%20combination%22
- ORCID: https://orcid.org/0000-0002-3116-3246